FRANKLIN M BERGER
CIK 1273885 · Director · last filed 2026-06-23
FRANKLIN M BERGER is a Director who has filed 118 SEC Form 4 insider transactions across 13 companies since 2007. The most recent filing, for AVIR, was dated Jun 23, 2026. Across all open-market trades the lifetime net is +$11.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.8M across reported positions. 3 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.77M
13
118
$11.27M
Filer Profile
225 FRANKLIN STREET SUITE 2100
BOSTON, MA
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVIR | Director | 536,097 | $5.17 | $2.77M | -$238.2K | 13 | 2026-06-23 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 0 | $7.29 | $0 | $2.91M | 14 | 2026-05-11 |
| ESSA Pharma Inc. (EPIX) Delisted | Director | 784,404 | $0.20 | $157.8K | $1.36M | 8 | 2024-03-28 |
| RAIN | Director | 0 | $1.00 | $0 | $3.41M | 8 | 2024-01-26 |
| Atreca, Inc. (BCEL) Delisted | Director | 97,808 | $0.15 | $14.7K | $0 | 5 | 2023-06-15 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | 0 | $38.00 | $0 | $1.20M | 13 | 2021-04-19 |
| KINETA, INC./DE (PTI) Delisted | Director | 15,308 | — | — | $2.12M | 10 | 2020-07-01 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | 1,689 | — | — | $0 | 4 | 2019-10-04 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | — | $178.75 | — | $0 | 4 | 2019-06-12 |
| Seagen Inc. (SGEN) Delisted | Director | 204,720 | $228.74 | $46.83M | $505.2K | 20 | 2014-02-25 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 500 | — | — | $1.9K | 2 | 2013-08-22 |
| EMIS | Director | — | $10.27 | — | $0 | 1 | 2009-05-19 |
| Diadexus, Inc. (AXC) Delisted | Director | — | — | — | $0 | 1 | 2008-06-11 |
Recent Filings
118 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | AVIR | Mixed | +29,600 | $0 | EDGAR |
| 2026-05-11 | Kezar Life Sciences, Inc. (KZR) Delisted | Mixed | −89,069 | $0 | EDGAR |
| 2025-10-15 | — | Disp (D) | −784,404 | $0 | |
| 2025-06-24 | AVIR | Mixed | +29,600 | $0 | EDGAR |
| 2025-06-23 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-17 | AVIR | Buy (P) | +25,000 | $81.5K | EDGAR |
| 2025-01-17 | AVIR | Buy (P) | −25,000 | -$81.5K | EDGAR |
| 2024-12-12 | AVIR | Sell (S) | −359,606 | -$1.02M | EDGAR |
| 2024-12-10 | AVIR | Notice (144) | −359,606 | -$1.02M | EDGAR |
| 2024-06-21 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.